Tumor Immunology Unveiled: Advances, Challenges, and Future Prospects in Cancer Immunotherapy
DOI:
https://doi.org/10.61173/9a77e006Keywords:
Tumor Immunology, Immune System, Immune Escape Mechanisms, Immune Checkpoint, Tumor VaccinesAbstract
Among the most important disciplines in the field of immunology, tumor immunology holds a significant place due to its focus on the interaction between tumors and the immune system. With the advancement of immunotherapy technologies in recent years, tumor immunology has emerged as one of the most exciting areas in cancer research. In this article, we will examine in detail the research progress in tumor immunology, including the mechanisms by which tumor cells evade the immune system, the application of immune checkpoint inhibitors, the development of tumor vaccines and their application in clinical practice, and how the tumor microenvironment impacts immunotherapy.
References
[1] Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion[J]. Nature Reviews Cancer, 2021, 21(5): 298- 312.
[2] Lowe K L, Cole D, Kenefeck R, et al. Novel TCR-based biologics: mobilising T cells to warm ‘cold’tumours[J]. Cancer treatment reviews, 2019, 77: 35-43.
[3] Youn J W, Hur S Y, Woo J W, et al. Pembrolizumab plus GX- 188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial[J]. The Lancet Oncology, 2020, 21(12): 1653-1660.
[4] Wculek S K, Cueto F J, Mujal A M, et al. Dendritic cells in cancer immunology and immunotherapy[J]. Nature Reviews Immunology, 2020, 20(1): 7-24.
[5] Palomares O, Martin-Fontecha M, Lauener R, et al. Regulatory T cells and immune regulation of allergic diseases: roles of IL-10 and TGF-β[J]. Genes & Immunity, 2014, 15(8): 511-520.
[6] Pandey P, Khan F, Qari H A, et al. Revolutionization in cancer therapeutics via targeting major immune checkpoints PD- 1, PD-L1 and CTLA-4[J]. Pharmaceuticals, 2022, 15(3): 335.
[7] Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death[J]. The EMBO journal, 1992, 11(11): 3887-3895.
[8] Brahmer J R, Drake C G, Wollner I, et al. Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates[J]. Journal of clinical oncology, 2010, 28(19): 3167-3175.
[9] Wojtukiewicz M Z, Rek M M, Karpowicz K, et al. Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4— new opportunities for cancer patients and a new challenge for internists and general practitioners[J]. Cancer and Metastasis Reviews, 2021, 40: 949-982.
[10] Zeng Z, Shi F, Zhou L, et al. Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma[J]. PloS one, 2011, 6(9): e23621.
[11] Carbone D P, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non–small-cell lung cancer[J]. New England Journal of Medicine, 2017, 376(25): 2415-2426.
[12] Kothapalli, A., & Khattak, M. A. (2018). Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small- Dean&Francis cell lung cancer in patients with viral hepatitis: a case series. Melanoma Research, 28(2), 155-158.
[13] Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer[J]. New England Journal of Medicine, 2015, 373(17): 1627-1639.
[14] Saxena M, Bhardwaj N. Re-emergence of dendritic cell vaccines for cancer treatment[J]. Trends in cancer, 2018, 4(2): 119-137.
[15] Harari A, Graciotti M, Bassani-Sternberg M, et al. Antitumour dendritic cell vaccination in a priming and boosting approach[J]. Nature Reviews Drug Discovery, 2020, 19(9): 635- 652.
[16] Tie Y, Tang F, Wei Y, et al. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets[J]. Journal of hematology & oncology, 2022, 15(1): 61.
[17] Cho J Y, Miller M, Baek K J, et al. Immunostimulatory DNA inhibits transforming growth factor-β expression and airway remodeling[J]. American journal of respiratory cell and molecular biology, 2004, 30(5): 651-661.
[18] Coppin C. Immunotherapy for renal cell cancer in the era of targeted therapy[J]. Expert Review of Anticancer Therapy, 2008, 8(6): 907-919.
[19] Capitini C M, Fry T J, Mackall C L. Cytokines as adjuvants for vaccine and cellular therapies for cancer[J]. American journal of immunology, 2009, 5(3): 65.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
